S/MARter Immunotherapies
Our Products
Cancer Vaccines
Tcelltech has also developed peptide vaccines targeting the two most common clonal driver mutations in incurable brain tumors (IDH1R132H and H3K27M).
Our IDH1 SCA-VAC has completed Phase I trial (32 patients, 21 grade 3, 11 grade 4), meeting both primary endpoints with very promising results (Reference: https://www.nature.com/articles/s41586-021-03363-z).
A subsequent randomized Phase 2 clinical trial is expected to start in 2026.
Our H3 SCA-VAC is currently in Phase I development in combination with Atezolizumab after successful first-in-human dosing (Reference: https://www.nature.com/articles/s41591-023-02555-6).
First data of the combination trial will be published in 2026.
Tumor-targeting T cell receptors
TCT-001 is a first-in-class T cell therapy for patients with glioblastoma employing T cells engineered with a proprietory T cell receptor targeting a glioblastoma antigen.
After successful preclinical development (Reference: https://www.nature.com/articles/s41467-025-56547-w) TCT-001 engineered with our nanoSMAR platform will start phase 1 testing in 2026.